H. Lundbeck A/S (Lundbeck) is selling its shares in the listed
company LifeCycle Pharma A/S and ownership interests in four small
private equity funds to the Lundbeck Foundation's investment and
holding company LFI a/s. The transaction is the result of Lundbeck's
decision to dispose of investments that are not of strategic
importance to the company.

"We aim to build Lundbeck into the world's leading pharmaceutical
company in the field of neurology, and activities that do not add any
strategic value will therefore be divested. We are pleased that this
divestment will strengthen the Lundbeck Foundation in its efforts to
become an active life science partner," says Lundbeck's CFO Anders
Götzsche.

For the Lundbeck Foundation, the transaction underlines the
foundation's new investment strategy, the cornerstone of which is
incremental investments in life science.

"Going forward, the Lundbeck Foundation will diversify its investment
strategy into more active operations, and this transaction is the
first example of the strategy. The shares and ownership interests
that we are taking over from Lundbeck are a perfect match for the
portfolio we are building. As a result, the transaction marks a
successful start to the investment initiatives we will pursue," says
Mogens Bundgaard-Nielsen, Chairman of the Lundbeck Foundation.

The shares in LifeCycle Pharma are traded at a price of DKK 18 per
share, corresponding to a total price of DKK 276 million, providing
Lundbeck with a profit of approximately DKK 124 million relative to
the carrying amount of the shares. The profit will be recognised as
revenue in Lundbeck's financial statements for the first quarter of
2009.

The ownership interests in the private equity funds are traded at a
price close to the net asset value. Over the years, the ownership
interests have been revalued over Lundbeck's equity and not the
profit and loss statement. Upon a sale of these assets, Lundbeck must
therefore expense any impairment charges made over the years. As a
result of the divestment, Lundbeck therefore expects to incur costs
of approximately DKK 96 million, which will be recognised as a
financial expense in the company's financial statements for the
fourth quarter of 2008. The exact figure is still unknown as the net
asset value of the private equity funds and, by extension, the
carrying amount in financial statements at 31 December 2008, remains
to be calculated.


Lundbeck Foundation/LFI a/s contacts


Mogens Bundgaard-Nielsen
Chairman
+45 35 26 16 19

Steen Hemmingsen
Managing Director
+45 39 12 80 00


Lundbeck contacts


Investors:                 Media:

Jacob Tolstrup             Mads Kronborg
Director                   External media
+45 36 43 30 79            +45 36 43 28 51

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


Corporate release No 364 - 27 January 2009

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of
pharmaceuticals for the treatment of psychiatric and neurological
disorders. In 2007, the company's revenue was DKK 11 billion
(approximately EUR 1.5 billion or USD 2.0 billion). The number of
employees is approx. 5,300 globally. For more information, please
visit www.lundbeck.com.


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.
http://hugin.info/130085/R/1285049/288037.pdf


Copyright © Hugin AS 2009. All rights reserved.